BAUSCH HEALTH COS INC

Explore Bausch Health’s steep stock decline, negative P/E, and R&D‑driven challenges—why investors worry about its future profitability.

Explore Bausch Health’s growing impact in pharma and vision care, its resilient stock performance, and how R&D‑driven innovations shape the future of health care.

Bausch Health Companies Inc. has extended its tender offer to acquire DURECT Corporation for $1.75 per share, with the offer now set to expire on September 10, 2025.

Bausch Health Companies Inc. is a pharmaceutical company navigating the sector’s unpredictability, with a fluctuating stock price and challenges in the global market, but remaining committed to innovation and addressing unmet medical needs.

Bausch Health Companies Inc. saw a 15.8% surge in its stock price on August 12, 2025, driven by bargain-hunting investors and a strategic acquisition of DURECT Corporation for $63 million.

Bausch Health Companies Inc. has seen a 15.8% stock price rebound and announced the acquisition of DURECT Corporation for $63 million, with potential for up to $350 million in milestone payments.

Bausch Health Companies Inc. has announced a plan to slash its debt by approximately $900 million using cash on hand, a bold move aimed at improving its financial health and capital structure.

Bausch Health Companies Inc. is a leading pharmaceutical company committed to innovation, global reach, and addressing unmet medical needs, positioning it as a key player in the future of medicine.